[Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma].
We compared serum levels of insulin-like growth factors (IGF) type 1 protein (IGFP-1) in prostatic cancer (PC) and prostatic adenoma (PA). Clinical and morphological characteristics of the diseases were taken into consideration. Concentration of total IGFP-1 in the serum was measured by solid-phase enzyme immunoassay with kits made by DSL, USA. Concentration of total PSA in the serum was measured with Boehringer Mannheim (Germany) kits. The examination covered 51 PC patients of group 1 (mean age 66.4 +/- 1.2 years) and 10 PA patients (mean age 66.9 +/- 2.7 years) of group 2. IGFP-1 in group 1 made up 67 +/- 5 ng/ml, in group 2 - 77 +/- 12 ng/ml (p < 0.4). Higher IGFP-1 levels in the serum of PA patients (96 +/- 14 ng/ml) are shown compared to PC patients (56 +/- 9.2 ng/ml) in PSA under 10 ng/ml (p = 0.033). Mean value of the proportion IGFP-1/PSA was 4.2 +/- 0.8 in PC and 15.4 +/- 3.6 in PA (p < 0.001). Sensitivity and specificity of IGFP-1 estimation for differential diagnosis of PC were 72.1 and 57.1%, respectively), of IGFP-1/PSA for differential diagnosis was 81.3 and 87.5%, respectively. Thus, serum IGFP-1/PSA ratio has high sensitivity and specificity for detection of PC.
Morozov
A P
AP
Trapeznikov
M F
MF
Kushlinskiĭ
N E
NE
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D003937:Diagnosis, Differential; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D018970:Insulin-Like Growth Factor Binding Protein 1; D017430:Prostate-Specific Antigen